EpiCept Reports New Data On Benefits Of Maintenance Therapy With Ceplene(R) And Interleukin-2 For AML Patients At ASH Annual Meeting

EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that new data on the benefits of maintenance therapy with Ceplene® (histamine dihydrochloride) and interleukin-2 (IL-2) for Acute Myeloid Leukemia (AML) patients in complete remission will be presented at the 50th American Society of Hematology (ASH) Annual Meeting being held December 6-9 at the Moscone Center in San Francisco.

More: continued here

Filed under: Blood on December 4th, 2008